Relationship of serum levels of interleukin-6, soluble interleukin-6 receptor and tumour necrosis factor receptors to the acute-phase protein response in advanced pancreatic cancer

Clinical Science

Volumn 96, Issue 1, 1999, Pages 83-87

  Barber, Matthew D ^a   Fearon, Kenneth C H ^a   Ross, James A ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Acute phase response; Interleukin 6; Pancreatic cancer; Soluble interleukin 6 receptor; Soluble tumour necrosis factor receptor

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ACUTE PHASE RESPONSE; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD LEVEL; CACHEXIA; CANCER SURVIVAL; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PANCREAS CANCER; PRIORITY JOURNAL;

ACUTE-PHASE REACTION; ADENOCARCINOMA; AGED; ANTIGENS, CD; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERLEUKIN-6; MIDDLE AGED; PANCREATIC NEOPLASMS; RECEPTORS, INTERLEUKIN-6; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; STATISTICS, NONPARAMETRIC;

EID: 0032933715     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS19980185     Document Type: Article

References (26)

1. 1 Rosewicz, S. and Weidenmann, B. (1997) Pancreatic carcinoma. Lancet 349, 485-489
2. 2 Ahlgren, J. D. (1996) Epidemiology and risk factors in pancreatic cancer. Semin. Oncol. 23, 241-250
3. 3 Wigmore, S. J., Plester, C. E., Richardson, R. A. and Fearon, K. C. H. (1997) Changes in nutritional status associated with unresectable pancreatic cancer. Br. J. Cancer 75, 106-109
4. 4 Fearon, K. C. H. (1992) The mechanisms and treatment of weight loss in cancer. Proc. Nutr. Soc. 51, 251-265
5. 5 Falconer, J. S., Fearon, K. C. H., Plester, C. E., Ross, J. A. and Carter, D. C. (1994) Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann. Surg. 219, 325-331
6. 6 Baumann, H. and Gauldie, J. (1994) The acute phase response. Immunol. Today 15, 74-80
7. 7 Falconer, J. S., Fearon, K. C. H., Ross, J. A. et al. (1995) Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 75, 2077-2082
8. 8 Heinrich, P. C., Castell, J. V. and Andus, T. (1990) Interleukin-6 and the acute phase response. Biochem. J. 265, 621-636
9. 9 Warren, R. S., Starnes, H. F., Gabrilove, J. L., Oettgen, H. F. and Brennan, M. F. (1987) The acute metabolic effects of tumor necrosis factor administration in humans. Arch. Surg. 122, 1396-1400
10. 10 Hohmann, H.-P., Remy, R., Brockhaus, M. and van Loon, A. P. G. M. (1989) Two different cell types have different major receptors for human tumor necrosis factor (TNFα). J. Biol. Chem. 264, 14927-14934
11. 11 Olsson, I., Gatanaga, T., Gullberg, U., Lantz, M. and Granger, G. A. (1993) Tumour necrosis factor binding proteins (soluble TNF receptor forms) with possible roles in inflammation and malignancy. Eur. Cytokine Network 4, 169-180
12. 12 Goldie, A. S., Fearon, K. C. H., Ross, J. A. et al. (1995) Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. J. Am. Med. Assoc. 274, 172-177
13. 13 Nakayama, T., Hashimoto, S., Amemiya, E. and Horie, T. (1996) Elevation of plasma-soluble rumour necrosis factor receptors in sarcoidosis. Clin. Exp. Immunol. 104, 318-324
14. 14 Yoshida, S., Hashimoto, S., Nakayama, T., Kobayashi, T., Koizumi, A. and Horie, T. (1996) Elevation of serum soluble rumour necrosis factor receptor and IL-1 receptor antagonist levels in bronchial asthma. Clin. Exp. Immunol. 106, 73-78
15. 15 Taga, T., Hibi, M., Hirata, Y. et al. (1989) Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58, 573-581
16. 16 Mackiewicz, A., Schooltink, H., Heinrich, P. C. and Rose-John, S. (1992) Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J. Immunol. 149, 2021-2027
17. 17 Tamura, T., Udagawa, N., Takahashi, N. et al. (1993) Soluble interleukin-6 receptor triggers osteoclast formation by interleukin-6. Proc. Natl. Acad. Sci. U.S.A. 90, 11924-11928
18. 18 Modur, V., Li, Y., Zimmerman, G. A., Prescott, S. M. and McIntyre, T. M. (1997) Retrograde inflammatory signalling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha. J. Clin. Invest. 100, 2752-2756
19. 19 Leeuwenberg, J. F. M., Jeunhomme, G. M. M. A. and Buurman, W. A. (1994) Slow release of soluble TNF-receptors by monocytes in vitro. J. Immunol. 152, 4036-4043
20. 20 Lavabre-Bertrand, T., Exbrayat, C., Liautard, J. et al. (1995) Detection of membrane and soluble interleukin-6 receptor in lymphoid malignancies. Br. J. Haematol. 91, 871-877
21. 21 Yokoyama, A., Kohno, N., Hirasawa, Y. et al. (1995) Evaluation of soluble IL-6 receptor concentration in serum and epithelial lining fluid from patients with interstitial lung disease. Clin. Exp. Immunol. 100, 325-329
22. 22 Suzuki, H., Yasukawa, K., Saito, T. et al. (1993) Serum soluble interleukin-6 receptor in MRL/lpr mice is elevated with age and mediates the interleukin-6 signal. Eur. J. Immunol. 23, 1078-1082
23. 23 Aderka, D., Engelmann, H., Hornik, V. et al. (1991) Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res. 51, 5602-5607
24. 24 Bonifati, C., Trento, E., Carducci, M. et al. (1995) Soluble E-selectin and soluble tumour necrosis factor receptor serum levels in patients with psoriasis. Dermatology 190, 128-131
25. 25 Kurzrock, R., Redman, J., Cabanillas, F., Jones, D., Rothberg, J. and Talpaz, M. (1993) Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res. 53, 2118-2122
26. 26 Preston, T., Fearon, K. C. H., McMillan, D. C. et al. (1995) Effect of ibuprofen on the acute-phase response and protein metabolism in patients with cancer and weight loss. Br. J. Surg. 82, 229-234